0001209191-23-018884.txt : 20230315 0001209191-23-018884.hdr.sgml : 20230315 20230315161445 ACCESSION NUMBER: 0001209191-23-018884 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230315 DATE AS OF CHANGE: 20230315 EFFECTIVENESS DATE: 20230315 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Virax Biolabs Group Ltd CENTRAL INDEX KEY: 0001885827 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 000000000 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-475980 FILM NUMBER: 23735347 BUSINESS ADDRESS: STREET 1: 30 BROADWICK STREET CITY: LONDON STATE: X0 ZIP: W1F 8LX BUSINESS PHONE: 44 020 7788 7414 MAIL ADDRESS: STREET 1: 30 BROADWICK STREET CITY: LONDON STATE: X0 ZIP: W1F 8LX FORMER COMPANY: FORMER CONFORMED NAME: Virax Biolabs (Cayman) Ltd DATE OF NAME CHANGE: 20210930 D 1 primary_doc.xml X0708 D LIVE 0001885827 Virax Biolabs Group Ltd 20 North Audley Street London X0 UNITED KINGDOM W1K 6LX 44 020 7788 7414 CAYMAN ISLANDS None Virax Biolabs (Cayman) Ltd Corporation true 2021 James Alexander Cunliffe Foster 20 North Audley Street London X0 UNITED KINGDOM W1K 6LX Executive Officer Director Cameron Shaw 20 North Audley Street London X0 UNITED KINGDOM W1K 6LX Executive Officer Director Evan Norton 20 North Audley Street London X0 UNITED KINGDOM W1K 6LX Director Yair Erez 20 North Audley Street London X0 UNITED KINGDOM W1K 6LX Director Nelson Maurice Haight 20 North Audley Street London X0 UNITED KINGDOM W1K 6LX Director Jason Davis 20 North Audley Street London X0 UNITED KINGDOM W1K 6LX Executive Officer Tomasz George 20 North Audley Street London X0 UNITED KINGDOM W1K 6LX Executive Officer Mark Ternouth 20 North Audley Street London X0 UNITED KINGDOM W1K 6LX Executive Officer Biotechnology $1 - $1,000,000 06b false 2023-03-10 false true true true false 0 H.C. Wainwright & Co. 375 None None 430 PARK AVENUE 4TH FLOOR NEW YORK NY NEW YORK 10022 All States 4000000 4000000 0 The offering includes the sale of warrants which are exercisable immediately after issuance. The above offering amount does not include the proceeds to be received by the Company upon exercise of the warrant. false 1 208000 0 The placement agent is also entitled to a management fee 40,000, non-accountable expenses $35,000, accountable expenses $50,000, and warrants to purchase up to 269,032 ordinary shares. 0 Issuer expects to use proceeds from the offering for working capital which includes payment of salaries to executive officers. false Virax Biolabs Group Ltd /s/ Jason Davis Jason Davis Chief Financial Officer 2023-03-14